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Objectives
An increasing proportion of people living with HIV are older adults, who may require specialized
care. Adverse physical and psychological effects of HIV infection may be greatest among older
people or those who have lived longer with HIV.
Methods
The ASTRA study is a cross-sectional questionnaire study of 3258 HIV-diagnosed adults (2248 men
who have sex with men, 373 heterosexual men and 637 women) recruited from UK clinics in 2011–
2012. Associations of age group with physical symptom distress (significant distress for at least one of
26 symptoms), depression and anxiety symptoms (scores ≥ 10 on PHQ-9 and GAD-7, respectively), and
health-related functional problems (problems on at least one of three domains of the Euroqol 5D-3L))
were assessed, adjusting for time with diagnosed HIV infection, gender/sexual orientation and ethnicity.
Results
The age distribution of participants was: < 30 years, 5%; 30–39 years, 23%; 40–49 years, 43%; 50–
59 years, 22%; and ≥ 60 years, 7%. Overall prevalences were: physical symptom distress, 56%;
depression symptoms, 27%; anxiety symptoms, 22%; functional problems, 38%. No trend was found in
the prevalence of physical symptom distress with age [adjusted odds ratio (OR) for trend across age
groups, 0.96; 95% confidence interval (CI) 0.89, 1.04; P = 0.36]. The prevalence of depression and
anxiety symptoms decreased with age [adjusted OR 0.86 (95% CI 0.79, 0.94; P = 0.001) and adjusted OR
0.85 (95% CI 0.77, 0.94; P = 0.001), respectively], while that of functional problems increased (adjusted
OR 1.28; 95% CI 1.17, 1.39; P < 0.001). In contrast, a longer time with diagnosed HIV infection was
strongly and independently associated with a higher prevalence of symptom distress, depression
symptoms, anxiety symptoms, and functional problems (P < 0.001 for trends, adjusted analysis).
Conclusions
Among people living with HIV, although health-related functional problems were more common
with older age, physical symptom distress was not, and mental health was more favourable. These
results suggest that a longer time with diagnosed HIV infection, rather than age, is the dominating
factor contributing to psychological morbidity and lower quality of life.
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Introduction
As a consequence of advances in treatment, people diag-
nosed with HIV infection have greatly improved life
expectancy [1]. In the UK, an estimated 27% of people
living with diagnosed HIV infection were aged 50 years or
over in 2013; this percentage has doubled in the past
decade [2], with newly diagnosed infections among older
people doubling in the same time period [2]. The Joint Uni-
ted Nations Programme on HIV/AIDS (UNAIDS) surmised
that, world-wide by 2013, 10% of people diagnosed with
HIV infection were over 50 years old and that in high-
income countries this was nearer a third [3]. Research into
this population’s requirements and experiences is impor-
tant [4–6]. However, few studies have examined the effect
of older age on wellbeing in people living with HIV.
Symptom prevalence is high in people living with HIV
even in the era of combination antiretroviral therapy
(cART) [7,8]. It has been suggested that adverse physical
and psychological effects of HIV infection may be great-
est among older people [4]. Older people with HIV infec-
tion may have been living with the diagnosis for many
years and may have ongoing health problems or disabil-
ity related to HIV infection, in addition to the age-related
morbidities common in the general population. HIV
infection and/or treatment has been implicated in a num-
ber of chronic conditions generally prevalent among
older people, including cardiovascular disease, dyslipi-
daemia and osteoporosis [9–11] and a high medication
burden is common among older people living with HIV
[12]. Immune activation and chronic inflammation are
associated with HIV infection and may be more prevalent
among older adults [13]. Later HIV diagnosis in older
adults can result in a lower likelihood of achieving
immune recovery with cART [6,14]. It is conceivable,
therefore, that HIV infection and older age could have
cumulative detrimental effects on health [15].
Depression is common among people living with HIV
[16,17]. Although there is a perception that older people
with HIV may be particularly vulnerable to depression as a
consequence of issues such as stigma and lack of social
support [4], the association between age and psychological
symptoms among people with HIV is unclear [6,16,18,19].
Quality of life has been defined as ‘multidimensional in
construct including physical, emotional, mental, social,
and behavioural components’ [6] and has been found to be
lower among older compared with younger people with
HIV [17], but the role of psychological, physical and func-
tional problems in this relationship is unclear.
As HIV infection is now a chronic condition, research
into the impact of age on wellbeing is increasingly rele-
vant to patient care. However, few studies have examined
the association of both age and time since HIV diagnosis
with self-rated health and symptoms. We examined these
questions in the Antiretrovirals, Sexual Transmission Risk
and Attitudes (ASTRA) study, a multicentre study of
people living with HIV in the UK. We have previously
reported that the health-related quality-of-life utility
score was lower among people with diagnosed HIV com-
pared with the UK general population, accounting for
major demographic factors [17]. The aim of this present
analysis was to assess, among people with diagnosed
HIV, the association of age with: (a) the prevalence of
physical symptoms causing distress, (b) the prevalence of
depression and anxiety symptoms and (c) the prevalence
of health-related functional problems, taking into account
time since HIV diagnosis and other demographic factors.
Methods
The ASTRA study recruited 3258 individuals diagnosed
with HIV infection from eight HIV out-patient clinics in
the UK from February 2011 to December 2012 (64%
response rate). Participants completed a self-administered
questionnaire on a range of socio-demographic, health,
HIV-related and lifestyle issues, and the clinic-recorded
viral load and CD4 count were documented. Further
details have been published [20].
In this analysis, information on physical symptoms,
depression and anxiety symptoms, and health-related func-
tional problems is reported in relation to age group, time with
diagnosed HIV infection, gender/sexual orientation and eth-
nicity.
Symptom measures
Physical symptoms were quantified using a modified Mem-
orial Symptom Assessment Scale-Short Form (MSAS-SF)
scale [21], listing 26 common symptoms (Table 1). Partici-
pants were asked to report whether each symptom was pre-
sent in the past 2 weeks, and, if so, to rank their distress on
a four-point scale: ‘did not bother me’; ‘bothered/distressed
a little bit’; ‘bothered/distressed quite a bit’; ‘bothered/dis-
tressed very much’. Symptoms were classified in two ways:
‘present’ (if the symptom was reported) and ‘distressing’ (if
the symptom ‘bothered/distressed quite a bit’ or ‘very
much’). ‘Physical symptom distress’ was defined as report-
ing at least one of the 26 symptoms as distressing. Several
symptom subgroups were considered (Table 1) where par-
ticipants were classified as positive if they reported at least
one of the symptoms in that category as distressing.
Depression symptoms and anxiety symptoms were
measured using standard symptom inventories (the
Patient Health Questionnaire, 9 item scale (PHQ-9) [22]
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and Generalized Anxiety Disorder 7 item scale (GAD-7)
[23]) that inquire about the frequency of occurrence of
specific symptoms in the past 2 weeks: depression and
anxiety were defined according to standard algorithms
based on a total score of 10 or more in each case.
A ‘health-related functional problem’ was defined as
reporting ‘some’ or ‘severe’ problems (rather than ‘no
problems’) on one of three functional domains (mobility,
self-care and daily activities) of a standard health-related
quality of life (HrQoL) measure, the Euroqol 5D 3L
(EQ-5D-3L) [24]. In addition, the three domains of the
EQ-5D-3L were considered separately.
Missing values for individual questions on symptom/
HrQoL questionnaires were counted as the absence of
symptoms. PHQ-9, GAD-7, modified MSAS-SF and the
three domains of the EQ-5D-3L are shown in Appendix 2.
Of note, both PHQ-9 and modified MSAS-SF incorporate
questions on tiredness, sleep, appetite and concentration.
Statistical analysis
Age was grouped as follows: < 30, 30–39, 40–49, 50–59
and ≥ 60 years. Differences in participant characteristics
by age group were assessed using v2 tests for trend.
Prevalences of physical symptom distress, depression,
anxiety and health-related functional problems were cal-
culated overall and by age group. Logistic regression was
used to assess the association between age group and
each of the health measures (dependent variables), adjust-
ing for gender/sexual orientation [men who have sex
with men (MSM), heterosexual men and women], ethnic-
ity [white and nonwhite/missing] and years with diag-
nosed HIV infection [< 2, 2-<5, 5-<10, 10-<15, 15-<20
and ≥ 20 years]. Age was fitted as a categorical variable
in the models. Tests for linear trend across categories
were also performed for age and years with diagnosed
HIV infection. Results are presented as adjusted odds
ratios (ORs) with 95% confidence intervals (CIs). Statisti-
cal significance was assessed using likelihood ratio tests.
Sensitivity analyses: (i) treating age and years with diag-
nosed HIV infection as continuous rather than categorical
variables (ii) additionally adjusting for university educa-
tion and (iii) additionally adjusting for clinical centre
yielded the same conclusions regarding trends (data not
shown).
Results
Subject characteristics
Of the 3258 study participants, 2248 (69.0%) were MSM,
373 (11.4%) were heterosexual men and 637 (19.6%) were
women. The mean age was 45 years [standard deviation
(SD) 9.6 years; range 18–88 years). Of 3190 participants
with age information, 172 (5.4%) were under 30 years
old, 745 (23.4%) 30–39 years old, 1370 (42.9%) 40–
49 years old, 689 (21.6%) 50–59 years old and 214
(6.7%) ≥ 60 years old. Time since diagnosis of HIV infec-
tion (n = 3230) was: 0–2 years for 373 patients (11.5%),
2–5 years for 498 (15.4%), 5–10 years for 893 (27.6%),
10–15 years for 647 (20.0%), 15–20 years for 488
(15.1%) and ≥ 20 years for 331 (10.2%). In terms of eth-
nic origin, 2220 (68.1%) participants were white, 614
(18.8%) were of black African ethnicity, 125 (3.8%) were
of other black ethnicity and 299 (9.2%) were of other/
missing ethnicity; 56.1% (1785 of 3183) of all partici-
Table 1 Prevalence of 26 physical symptoms and physical symptom
distress in the past 2 weeks in the study participants (N = 3258)
Symptom
Distressing¶
Present
n (%) n (%)
% of
‘present’
Lack of energy 2116 (64.9) 844 (25.9) 39.9
Feeling drowsy/tired 2105 (64.6) 790 (24.2) 37.5
Difficulty sleeping 1890 (58.0) 796 (24.4) 42.1
Muscle aches or joint pains 1740 (53.4) 678 (20.8) 39.0
Trouble remembering things 1676 (51.4) 569 (17.5) 33.9
Problems with sexual
interest/activity
1530 (47.0) 627 (19.2) 41.0
Difficulty concentrating 1514 (46.5) 462 (14.2) 30.5
Skin problems (e.g. rash,
itching or dryness)
1375 (42.2) 430 (13.2) 31.3
Numbness, tingling or
pain in hands or feet
1338 (41.1) 514 (15.8) 38.4
Headache 1294 (39.7) 343 (10.5) 26.5
Pain 1282 (39.3) 586 (18.0) 45.7
Feeling bloated 1253 (38.5) 366 (11.2) 29.2
Diarrhoea 1201 (36.9) 358 (11.0) 29.8
Sweats/fever 1192 (36.6) 412 (12.6) 34.6
Shortness of breath 1056 (32.4) 340 (10.4) 32.2
Cough 981 (30.1) 242 (7.4) 24.7
Dry mouth 970 (29.8) 226 (6.9) 23.3
Dizziness 961 (29.5) 293 (9.0) 30.5
Changes in fat in face or body 947 (29.1) 428 (13.1) 45.2
Nausea 811 (24.9) 221 (6.8) 27.3
Lack of appetite 754 (23.1) 204 (6.3) 27.1
Constipation 663 (20.3) 199 (6.1) 30.0
Changes in way food tastes 564 (17.3) 159 (4.9) 28.2
Weight loss 543 (16.7) 191 (5.9) 35.2
Mouth sores 531 (16.3) 155 (4.8) 29.2
Vomiting 392 (12.0) 125 (3.8) 31.9
Combined symptom categories
Sleep/energy/tiredness problems* 2522 (77.4) 1140 (35.0) 45.2
Concentration/memory problems† 1927 (59.1) 736 (22.6) 38.2
Pain/headache‡ 1746 (53.6) 688 (21.1) 39.4
Gastrointestinal symptoms§ 1986 (61.0) 704 (21.6) 35.4
*Includes ‘lack of energy’, ‘feeling drowsy/tired’ and ‘difficulty sleeping’.
†Includes ‘trouble remembering things’ and ‘difficulty concentrating’.
‡Includes ‘pain’ and ‘headache’.
§Includes ‘feeling bloated’, ‘diarrhoea’, ‘nausea’, ‘constipation’ and ‘vomit-
ing’.
¶Symptom causes ‘quite a bit of’ or ‘very much’ distress.
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pants were born in the UK. Over half of participants
(1821 of 3174; 57.4%) were employed, 577 (18.2%) were
unemployed, 420 (13.2%) were not working because of
sickness/disability, 192 (6.0%) were retired, and 164
(5.2%) were students, took care of the home, or other. A
high proportion of participants were university educated
(1317; 40.4%). Overall, 86.5% (2771 of 3202) of partici-
pants were on ART, 76.2% (2466 of 3237) had viral load
(VL) ≤ 50 HIV-1 RNA copies/mL and 18.5% (599 of 3235)
had CD4 count < 350 cells/lL.
Older participants were more likely to be male (88.8%
for age ≥ 60 years vs. 68.6% for age < 30 years;
P < 0.001, v2 test for trend across all age groups), of white
ethnicity (77.1% vs. 58.1%, respectively; P < 0.001), to
have been born in the UK (70.0% vs. 51.5%, respectively;
P < 0.001), to have been diagnosed with HIV infection for
more than 10 years (63.0% vs. 5.3%, respectively;
P < 0.001), to be on ART (93.8% vs. 60.9%, respectively;
P < 0.001) and to have VL ≤ 50 copies/mL (88.7% vs.
48.8%, respectively; P < 0.001). Older people were less
likely to be employed (19.7% vs. 60.9% for age ≥ 60 years
vs. < 30 years, respectively; P < 0.001) No significant
trend with age was found for university education (33.6%
vs. 35.5%, respectively; P = 0.11) or CD4 count < 350
cells/lL (19.3% vs. 23.4%, respectively; P = 0.69).
Physical symptom distress
Table 1 reports the prevalence of each symptom accord-
ing to whether it was (i) present and (ii) distressing. At
least one symptom was reported as ‘distressing’ by 55.6%
of participants (1811 of 3258), while 11.0% reported ten
or more distressing symptoms. The five most prevalent
distressing symptoms were ‘lack of energy’ (25.9%), ‘diffi-
culty sleeping’ (24.4%), ‘feeling drowsy/tired’ (24.2%),
‘muscle aches or joint pains’ (20.8%) and ‘problems with
sexual interest/activity’ (19.2%). Although lower in
prevalence, ‘pain’ and ‘changes in fat’ were more likely to
cause distress when present than other symptoms.
The three most prevalent distressing symptoms within
age groups were the same for each of the four age groups
under 60 years: ‘lack of energy’ (22.1–30.9%), followed
by ‘feeling drowsy/tired’ (20.0–28.4%) and ‘difficulty
sleeping’ (21.7–26.7%), and the proportion who reported
no distressing symptoms ranged from 38.8% to 48.6%.
Among participants aged ≥ 60 years the pattern was dif-
ferent: ‘muscle ache/joint pains’ was the most prevalent
distressing symptom (23.8%), followed by ‘pain’ (18.2%)
and ‘lack of energy’ (18.2%), but 47.7% of participants
reported no distressing symptoms.
Figure 1a shows the prevalence of physical symptom
distress overall and for selected common symptoms and
symptom subgroups by age group. The prevalence of over-
all symptom distress tended to increase slightly with age
over the 30–59-year age range, but was lower in the ≥ 60-
year age group. Interestingly, participants aged < 30 years
tended to have a higher prevalence of distressing symp-
toms compared with those aged 30–40 years, and com-
pared with the ≥ 60-year age group. Most of the symptom
groups followed this pattern, with ‘muscle-ache/joint pain’,
‘numbness/tingling/pain in the hands/feet’ and ‘pain’ hav-
ing the strongest increases with age.
The adjusted association of age with physical symptom
distress is presented in Table 2. After adjustment for gen-
der/sexual orientation, time with diagnosed HIV infection
and ethnicity, there was no trend with age group in the
prevalence of overall physical symptom distress. For
‘numbness/tingling/pain in the hands or feet’ and ‘muscle
ache/joint pain’, however, there was a significant increase
in prevalence with age, while for ‘problems with sexual
interest/activity’ there was a significant decrease with
age. However, for all symptom subgroups, the prevalence
of distressing symptoms was lower among those aged
≥ 60 years than those aged 50–60 years. In fact, for
many symptom groups, participants aged ≥ 60 years had
the lowest prevalence of distressing symptoms overall.
Time with diagnosed HIV infection was strongly related
to the prevalence of overall physical symptom distress
and each symptom subgroup: those diagnosed for longer
were more likely to report distressing symptoms (test for
trend across categories P < 0.001 for overall symptom
distress and all symptom measures in adjusted models,
Table 2). There were also differences by gender/sexual
orientation. For many symptom subgroups, the pattern
was similar: compared with MSM, the prevalence of dis-
tressing symptoms tended to be somewhat lower among
heterosexual men, and somewhat higher among women.
There were few significant differences according to
ethnicity.
Psychological symptoms
Depression (assessed using PHQ-9) was apparent in 27.1%
(884 of 3258) of participants and anxiety (assessed using
GAD-7) in 21.9% (715 of 3258). Figure 1b shows the asso-
ciations with age. The prevalence of symptoms of depres-
sion tended to decrease with age, being highest in the
< 30-year age group, similar across the three age groups
from 30 to 59 years, and lowest in those aged ≥ 60 years.
The prevalence of anxiety also tended to decrease with age,
following a similar pattern and being lowest among the
≥ 60-year age group. These patterns of decreasing preva-
lence with age were stronger in the adjusted analysis
(Table 3). However, in contrast to older age, longer time
© 2016 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association HIV Medicine (2017), 18, 89--103
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Fig. 1 Prevalences (%) of (a) distressing physical symptoms, (b) depression and anxiety symptoms, and (c) health-related functional problems by
age group. Physical symptom distress was defined using modified MSAS-SF (see Table 1); depression symptoms were defined as a PHQ-9 score
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with diagnosed HIV infection was strongly associated with
a higher prevalence of both depression and anxiety
(P < 0.001, for trend across categories for each in adjusted
models). There were no significant differences according to
gender/sexual orientation or ethnicity.
Health-related functional problems
The prevalence of health-related functional problems was
38.1% (1240 of 3258) overall and the prevalence of indi-
vidual domains was: mobility problems, 27.1%; self-care
problems, 12.3%; and problems performing usual activity,
32.1%. Few participants (< 3%) reported ‘extreme’ prob-
lems with mobility, self-care or usual activities. Figure 1c
shows that the prevalence of health-related functional
problems tended to increase with age for the overall mea-
sure and all three domains.
Table 4 shows that patterns were similar in adjusted
analysis. The prevalence of functional problems signifi-
cantly increased with age. As was the case for the physi-
cal and psychological symptom measures, longer time
since HIV diagnosis was strongly associated with a
greater prevalence of functional problems, both overall
and for each domain (P < 0.001 for trend across cate-
gories in adjusted models). In addition, mobility problems
tended to be more common among women compared
with MSM. There were no significant differences by eth-
nicity.
Discussion
In this large multicentre cross-sectional UK study, with
older age, people living with HIV reported a higher
prevalence of health-related functional problems, but a
lower prevalence of depression and anxiety symptoms.
There was no trend with age in the prevalence of overall
physical symptom distress, but the pattern varied accord-
ing to the specific symptom. Longer time with diagnosed
HIV infection, however, was related to a higher preva-
lence of all self-rated health problems: symptom distress,
depression, anxiety and each domain of functional prob-
lems, independently of age.
In our study, as found in the international START
(Strategic Timing of AntiRetroviral Treatment) trial popu-
lation at baseline, [25], the prevalence of problems with
physical mobility and daily function (assessed using the
EQ-5D-3L) increased with age, probably as a result pri-
marily of an increasing prevalence of chronic illness and
disability. Age was not significantly associatied with
overall physical symptom distress, but prevalence did
increase with age for specific symptom groups (muscle
ache/joint pain, and numbness/tingling/pain in hands orTa
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feet). However, we found a lower prevalence of distress-
ing symptoms in the over-60s group compared with
younger age groups, both overall and for many symptom
subgroups. This could, in part, be attributable to older
adults attributing health changes to natural ageing and
therefore not rating them as distressing [26,27]. Previous
research also posits that older adults may face fewer
high-demand situations as a consequence of retirement,
leaving increased time and mental reserves for coping with
physical distress [28]. It could also reflect ‘resilience’ in
older HIV-diagnosed people, lower expectations of good
health, or greater tolerance of poor health function [29].
In terms of mental health, the prevalence of depression
and anxiety, assessed using standardized symptom ques-
tionnaires, tended to decrease with age, a trend that
became more marked after adjustment for time with diag-
nosed HIV infection. In particular, the prevalences of
depression and anxiety were lower in the over-60s com-
pared with all other age groups. Interestingly, when anal-
ysed by individual questions, the decreasing prevalence
with age was more apparent for ‘psychological’ symptoms
of depression such as ‘feeling down’ or ‘thoughts you
would be better off dead’, than for ‘physical’ symptoms
of depression, such as ‘feeling tired’ or ‘appetite problems’
(data on request). It is possible that deteriorating physical
health in older age, or ageing with HIV infection, in
addition to depression contributes to these ‘physical’
symptoms [30], or that in older adults depression is
defined more often by somatic, rather than psychological,
symptoms [31]. It has been suggested that the burden of
psychological symptoms is high among older people liv-
ing with HIV [6,32,33], although few studies have
assessed the association between age and anxiety. Our
results showed a lower prevalence of psychological symp-
toms among older people living with HIV, which could
be mediated by improved social, behavioural or economic
circumstances in the older population (such as reduced
recreational drug use). It is possible that the lower preva-
lences of anxiety and depression among older compared
with younger people living with HIV reflect better adap-
tation to hardship in older adults, developed through
their lifespan [34,35], or ‘resilience’ [36], which has been
found to be high in older HIV-diagnosed people [28,37].
Alternatively, this could be an example of ‘successful
ageing’ in HIV-diagnosed people; the ability to maintain
mental health despite age-related health losses [37]. How-
ever, it could also reflect a ‘survivor’ selection effect
towards psychological wellbeing.
The overall prevalence of health-related functional
problems, as assessed by three domains of the EQ-5D-3L,
Table 3 Adjusted association of age, time with diagnosed HIV infection, gender/sexual orientation and ethnicity with psychological symptoms
(N = 3167)
Depression (score ≥ 10 on PHQ-9) Anxiety (score ≥ 10 on GAD-7)
Independent variable P-value Adjusted odds ratio* 95% CI P-value Adjusted odds ratio* 95% CI
Age < 0.001 < 0.001
< 30 years 3.52 (2.13, 5.81) 4.13 (2.35, 7.26)
30–39 years 1.93 (1.28, 2.91) 2.35 (1.46, 3.79)
40–49 years 2.17 (1.48, 3.19) 2.59 (1.65, 4.06)
50–59 years 2.06 (1.38, 3.07) 2.48 (1.56, 3.94)
≥ 60 years‡ 1 1
Test for trend† 0.001 0.86 (0.79, 0.94) 0.001 0.85 (0.77, 0.94)
Years with diagnosed HIV infection < 0.001 < 0.001
0–2 years‡ 1 1
2–5 years 0.93 (0.67, 1.30) 1.20 (0.83, 1.73)
5–10 years 1.36 (1.01, 1.82) 1.75 (1.26, 2.44)
10–15 years 1.41 (1.03, 1.93) 1.48 (1.04, 2.11)
15–20 years 1.85 (1.33, 2.55) 2.23 (1.55, 3.20)
≥ 20 years 2.31 (1.63, 3.28) 2.85 (1.93, 4.20)
Test for trend† < 0.001 1.20 (1.13, 1.27) < 0.001 1.21 (1.13, 1.29)
Gender/sexual orientation 0.63 0.22
MSM‡ 1 1
Heterosexual men 0.95 (0.71, 1.27) 1.02 (0.74, 1.39)
Women
0.56
1.10 (0.85, 1.41)
0.16
1.25 (0.96, 1.62)
Ethnicity
White‡ 1 1
Other ethnicity 1.07 (0.86, 1.33) 1.19 (0.94, 1.50)
*Multivariable logistic regression model including all factors in table. P-values obtained using likelihood ratio test.
†Linear trend across groups.
‡Reference group.
CI, confidence interval; MSM, men who have sex with men.
‘other ethnicity’ includes missing values.
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increased with age. Similar patterns of results were found
in other cross-sectional studies. A study using the WHO-
QOL-HIV [38] across eight (mainly low-income) countries
found physical symptoms tended to be more common for
older HIV-diagnosed people but mental health aspects
were more favourable. Similarly, in the international
START trial population, overall quality of life and the
physical health component decreased with age, but the
mental health component improved [25]. A multicentre
US study found few differences by age in health-related
quality of life among HIV-diagnosed people [18] using
the HAT-Quality of Life scale, but in this scale daily
function has a smaller role and psychosocial measures
take precedence [39]. These results highlight the sensitiv-
ity of quality of life analyses to the specific instrument
used, and weighting of domains within that instrument,
and emphasize the importance of understanding contrast-
ing trends across different health domains.
In contrast to older age, longer time with diagnosed
HIV infection was strongly and independently related to
poorer physical and psychological health across all mea-
sures studied, suggesting it may be a more important fac-
tor than chronological age in determining wellbeing
among people living with HIV. The association between
longer time with diagnosed HIV infection and poorer
health is likely to be related to earlier calendar time of
diagnosis: having been diagnosed at a time when HIV
prognosis was poor, treatments were less effective or
more complex, HIV-related stigma was greater, and com-
panions and supportive networks may have been lost.
However, it may also be related to increased time living
with a chronic disease and its health and social implica-
tions, younger age at HIV diagnosis, the effects of pro-
longed HIV treatment, or the effect of longer time with
untreated HIV infection specifically. The fact that, for
most of the health measures, an association with time
with diagnosed HIV infection was apparent even within
the group diagnosed in the last ten years (from 2001/
2002 to 2011/2012; a time of good prognosis) may give
some support to the latter explanations as contributing
factors. Future studies are needed to explore whether the
strong effect of time with diagnosed HIV on health mea-
sures is related to ageing with HIV infection, or whether
it primarily represents a historical effect of diagnosis in
the pre-cART or early cART eras. Research assessing the
effects on health of cumulative time with detectable vs
undetectable viral load may also be valuable.
Studies assessing self-reported symptoms among people
living with HIV are an important addition to those based
on clinic data, as they provide information on health
from the participant’s perspective. ASTRA is the largest
questionnaire study of HIV-diagnosed individuals in the
UK to date, and one of the few to examine associations
of age with symptoms, having accounted for time with
diagnosed HIV infection. However, our study has several
limitations. We have previously compared health-related
quality of life utility score (using EQ-5D-3L) between the
ASTRA participants and a large UK general population
sample [17], but unfortunately there is no corresponding
contemporary information on the prevalence of symp-
toms assessed using PHQ-9/GAD-7/MSAS-SF from UK
general population studies to compare with results for the
ASTRA sample. The study response rate was 64% overall,
but there may have been differential nonresponse accord-
ing to age which could cause bias in the assessment of
age trends. Very few of the participants had severe
mobility problems, which may be correlated to the ability
to attend the clinic, and so may exclude a group with
very poor health. Grouping all adults over 60 years old
together prevents us from identifying age differences
within this subgroup.
We aimed to assess the association of age with
self-reported health measures with adjustment for key
demographic factors for which the causal direction of
association would be uncontroversial. Socio-economic
[40–42], HIV- and treatment-related [43,44], and lifestyle
factors are worthy of future study as potential con-
founders or mediators of age effects.
Implications
This paper presents findings of age-related differences in
wellbeing among people living with HIV and the inde-
pendent effect of time with diagnosed HIV infection.
Older people living with HIV are increasing in number
globally [3] and health care systems will need to adapt to
meet the needs of this ageing population. Quality of life,
autonomy and self-rated health are essential components
of successful ageing [34,45]; our findings should inform
the development of appropriate services for older HIV-
positive people. These data do not support the hypothesis
that older compared with younger people living with HIV
have a disproportionate burden of symptoms. As psycho-
logical health appeared to be better among older partici-
pants, further exploration of ‘successful ageing’ among
people with HIV and the positive effects of age on coping
would be of value.
However, the strong and consistent associations
between longer time with diagnosed HIV infection and
poorer self-reported health, even after accounting for age,
suggest the need for supportive strategies for people who
have lived with HIV for a long period of time (including
those diagnosed in the pre-cART period, or as younger
adults), and emphasize the importance of regular care,
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and ongoing evaluation of psychological health, even for
individuals who are virologically stable on ART. Indepen-
dent associations of both older age and longer time since
HIV diagnosis with physical health problems emphasize
the importance of screening and assessment for age-
related conditions among people under care for HIV
infection, and prompt referral to suitable services.
For many symptom measures, we did not find continu-
ous trends with age. Grouping older people together in
an over-50s age group may miss important differences,
such as possible improvements in symptom burden with
older age. As the HIV-positive population ages, it will be
important for future research to examine older age
groups separately, as well as account for time since HIV
diagnosis.
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Appendix 2: Symptom questionnaires
Modified MSAS-SF
PHQ-9 and GAD-7
Below is a list of symptoms. Did you have any of these symptoms during the PAST 2 WEEKS? Please tick one box in each row to tell us
whether you have had the symptom and, if so, how much it DISTRESSED or BOTHERED you.
Did you have any of these symptoms during the PAST 2 WEEKS? No did not have the symptom
Yes, had
symptom
but it
DID NOT
BOTHER ME
Yes, had
symptom
and was
bothered/
distressed
A LITTLE BIT
Yes, had
symptom
and was
bothered/
distressed
QUITE A BIT
Yes, had
symptom
and was
bothered/
distressed
VERY MUCH
1. Difficulty concentrating □ □ □ □ □
2. Difficulty sleeping □ □ □ □ □
3. Lack of energy □ □ □ □ □
4. Feeling drowsy/tired □ □ □ □ □
5. Trouble remembering things □ □ □ □ □
6. Pain □ □ □ □ □
7. Headache □ □ □ □ □
8. Numbness, tingling
or pain in hands or feet
□ □ □ □ □
9. Muscle aches or joint pains □ □ □ □ □
10. Nausea □ □ □ □ □
11. Vomiting □ □ □ □ □
12. Diarrhoea □ □ □ □ □
13. Constipation □ □ □ □ □
14. Feeling bloated □ □ □ □ □
15. Dizziness □ □ □ □ □
16. Sweats/fever □ □ □ □ □
17. Cough □ □ □ □ □
18. Shortness of breath □ □ □ □ □
19. Problems with sexual interest/activity □ □ □ □ □
20. Skin problems (e.g. rash, itching, dryness) □ □ □ □ □
21. Dry mouth □ □ □ □ □
22. Mouth sores □ □ □ □ □
23. Lack of appetite □ □ □ □ □
24. Changes in way food tastes □ □ □ □ □
25. Weight loss □ □ □ □ □
26. Changes in fat in face or body □ □ □ □ □
Over the PAST 2 WEEKS, how often have you been bothered by any of the following problems?
Please tick one box in each row.
Not at
all
Several
days
More than
half the days
Nearly
every day
PHQ-9
(1) Little interest or pleasure in doing things □ □ □ □
(2) Feeling down, depressed, or hopeless □ □ □ □
(3) Trouble falling or staying asleep,
or sleeping too much
□ □ □ □
(4) Feeling tired or having little energy □ □ □ □
(5) Poor appetite or overeating □ □ □ □
(6) Feeling bad about yourself—or that
you are a failure or have let yourself or
your family down
□ □ □ □
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EUROQOL 5D 3L – first three domains
Appendix 2: Continued
Not at
all
Several
days
More than
half the days
Nearly
every day
(7) Trouble concentrating on things, such
as reading the newspaper or watching
television
□ □ □ □
(8) Moving or speaking so slowly that other
people could have noticed. Or the
opposite – being so fidgety or restless
that you have been moving around a
lot more than usual
□ □ □ □
(9) Thoughts that you would be better off dead,
or of hurting yourself in some way
□ □ □ □
GAD-7
Over the PAST 2 WEEKS, how often have you been bothered by any of the following problems?
Please tick one box in each row.
(1) Feeling nervous, anxious or on edge □ □ □ □
(2) Not being able to stop or control worrying □ □ □ □
(3) Worrying too much about different things □ □ □ □
(4) Trouble relaxing □ □ □ □
(5) Being so restless that it is hard to sit still □ □ □ □
(6) Becoming easily annoyed or irritable □ □ □ □
(7) Feeling afraid as if something awful
might happen
□ □ □ □
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